These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 28036259)

  • 1. Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells.
    Kim HJ; Lee SY; Kim CY; Kim YH; Ju W; Kim SC
    Oncotarget; 2017 Jan; 8(4):6608-6622. PubMed ID: 28036259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
    Wang L; Šuštić T; Leite de Oliveira R; Lieftink C; Halonen P; van de Ven M; Beijersbergen RL; van den Heuvel MM; Bernards R; van der Heijden MS
    Eur Urol; 2017 Jun; 71(6):858-862. PubMed ID: 28108151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells.
    Arjumand W; Merry CD; Wang C; Saba E; McIntyre JB; Fang S; Kornaga E; Ghatage P; Doll CM; Lees-Miller SP
    Oncotarget; 2016 Dec; 7(50):82424-82439. PubMed ID: 27489350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy.
    Peng X; Zhang S; Jiao W; Zhong Z; Yang Y; Claret FX; Elkabets M; Wang F; Wang R; Zhong Y; Chen ZS; Kong D
    J Exp Clin Cancer Res; 2021 Nov; 40(1):374. PubMed ID: 34844627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
    Wang D; Li C; Zhang Y; Wang M; Jiang N; Xiang L; Li T; Roberts TM; Zhao JJ; Cheng H; Liu P
    Gynecol Oncol; 2016 Sep; 142(3):548-56. PubMed ID: 27426307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells.
    Hu Y; Guo R; Wei J; Zhou Y; Ji W; Liu J; Zhi X; Zhang J
    Cell Death Dis; 2015 Dec; 6(12):e2020. PubMed ID: 26673665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade efficacy of MEK/ERK-dependent autophagy enhances PI3K/Akt inhibitor NVP-BKM120's therapeutic effectiveness in lung cancer cells.
    Ren H; Guo H; Thakur A; Zhang S; Wang T; Liang Y; Shi P; Gao L; Liu F; Feng J; Chen T; Yang T; Shang D; Liu JJ; Xu F; Chen M
    Oncotarget; 2016 Oct; 7(41):67277-67287. PubMed ID: 27572309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.
    Rexer BN; Chanthaphaychith S; Dahlman K; Arteaga CL
    Breast Cancer Res; 2014 Jan; 16(1):R9. PubMed ID: 24451154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer.
    Wang D; Wang M; Jiang N; Zhang Y; Bian X; Wang X; Roberts TM; Zhao JJ; Liu P; Cheng H
    Oncotarget; 2016 Mar; 7(11):13153-66. PubMed ID: 26909613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
    Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
    Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
    Yun MR; Choi HM; Kang HN; Lee Y; Joo HS; Kim DH; Kim HR; Hong MH; Yoon SO; Cho BC
    Oncogene; 2018 Jan; 37(3):377-388. PubMed ID: 28945228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tumor effects of NVP-BKM120 alone or in combination with MEK162 in biliary tract cancer.
    Jin L; Jin MH; Nam AR; Park JE; Bang JH; Oh DY; Bang YJ
    Cancer Lett; 2017 Dec; 411():162-170. PubMed ID: 29024814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.
    Mueller A; Bachmann E; Linnig M; Khillimberger K; Schimanski CC; Galle PR; Moehler M
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1601-15. PubMed ID: 22543857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.
    Maira SM; Pecchi S; Huang A; Burger M; Knapp M; Sterker D; Schnell C; Guthy D; Nagel T; Wiesmann M; Brachmann S; Fritsch C; Dorsch M; Chène P; Shoemaker K; De Pover A; Menezes D; Martiny-Baron G; Fabbro D; Wilson CJ; Schlegel R; Hofmann F; García-Echeverría C; Sellers WR; Voliva CF
    Mol Cancer Ther; 2012 Feb; 11(2):317-28. PubMed ID: 22188813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elucidating the role of the FoxO3a transcription factor in the IGF-1-induced migration and invasion of uveal melanoma cancer cells.
    Yan F; Liao R; Farhan M; Wang T; Chen J; Wang Z; Little PJ; Zheng W
    Biomed Pharmacother; 2016 Dec; 84():1538-1550. PubMed ID: 27881235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Licochalcone A induces autophagy through PI3K/Akt/mTOR inactivation and autophagy suppression enhances Licochalcone A-induced apoptosis of human cervical cancer cells.
    Tsai JP; Lee CH; Ying TH; Lin CL; Lin CL; Hsueh JT; Hsieh YH
    Oncotarget; 2015 Oct; 6(30):28851-66. PubMed ID: 26311737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma.
    Zang C; Eucker J; Liu H; Coordes A; Lenarz M; Possinger K; Scholz CW
    Leuk Lymphoma; 2014 Feb; 55(2):425-34. PubMed ID: 23721513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular effects of the phosphatidylinositol-3-kinase inhibitor NVP-BKM120 on T and B-cell acute lymphoblastic leukaemia.
    Pereira JK; Machado-Neto JA; Lopes MR; Morini BC; Traina F; Costa FF; Saad ST; Favaro P
    Eur J Cancer; 2015 Sep; 51(14):2076-85. PubMed ID: 26238016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.
    Vora SR; Juric D; Kim N; Mino-Kenudson M; Huynh T; Costa C; Lockerman EL; Pollack SF; Liu M; Li X; Lehar J; Wiesmann M; Wartmann M; Chen Y; Cao ZA; Pinzon-Ortiz M; Kim S; Schlegel R; Huang A; Engelman JA
    Cancer Cell; 2014 Jul; 26(1):136-49. PubMed ID: 25002028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.
    Bieniasz M; Radhakrishnan P; Faham N; De La O JP; Welm AL
    Clin Cancer Res; 2015 Dec; 21(24):5588-600. PubMed ID: 26289070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.